The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)

This study has been completed.
Sponsor:
Information provided by:
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00358306
First received: July 28, 2006
Last updated: February 16, 2010
Last verified: February 2010

July 28, 2006
February 16, 2010
April 2008
July 2009   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00358306 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)
The Role of Endothelium Dysfunction in Progression of CKD (Chronic Kidney Disease) After AKI (Acute Kidney Injury)

To understand how AKI (Acute Kidney Injury) leads to chronic kidney disease so therapies can be found to alter the progression of events thereby significantly impacting the long-term outcomes of children who develop AKI.

This research study is designed to study what happens to the kidneys after they have an injury. There is some evidence that even if there appears to be great improvement of kidney function, an injury can put patients at risk for long-term problems with their kidney function and increase their risk to have high blood pressure. We want to collect information from participants to help explain why this injury can cause future problems, including Chronic Kidney Disease (CKD) which may help us prevent these health problems.

Observational
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

Children 2-20 years old with history of acute kidney injury

  • Acute Renal Failure
  • Chronic Kidney Failure
  • Endothelial Dysfunction
  • Hemolytic-uremic Syndrome (HUS)
Not Provided
a
those with previous history of Acute kidney injury
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
36
July 2009
July 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children between age 2-20
  • Decrease in renal function by 25% or greater
  • Renal function has returned to normal

Exclusion Criteria:

  • History of chronic disease
  • Cancer
  • Congenital heart disease
  • Organ Transplantation
  • Liver disease
  • Pulmonary disease
  • Diabetes other primary metabolic condition
  • Severe neurologic impairments
  • Hypertension
  • Auto-immune
  • Infectious disease or renal disease
  • Smokers
  • Renal disease w/primary cause i.e. - HUS or Glomerulonephritis
  • severe allergies including allergy to seafood and/or iodine
Both
2 Years to 20 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00358306
F070309010
Yes
David Askenazi M.D., UAB
University of Alabama at Birmingham
Not Provided
Principal Investigator: David Askenazi, MD UAB Pediatric Nephrology
University of Alabama at Birmingham
February 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP